Clinical Trial Update: Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of BTX-A-HAC NG in treating glabellar lines has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cosmetic Facial Lines
• Glabellar Lines

Drugs mentioned

• Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) (botulinum toxin type A haemagglutinin complex next generation)

Snippet

Sponsor: Ipsen | Conditions: Glabellar Lines | Phase 3 | Status: COMPLETED | Results posted: 2019-05-28